Aratana Therapeutics, Inc. (Nasdaq: PETX), a pet therapeutics company focused on the development and commercialization of innovative therapeutics for dogs and cats, today announced the voting results for the three proposals considered and voted upon by its stockholders at its Special Meeting on July 16, 2019. The Company reported approximately 72% (35,269,237) of the Company’s common stock outstanding as of the July 14, 2019 record date adopted the merger agreement.
Approximately 73% (35,769,162) of the Company’s outstanding common stock as of the June 14, 2019 record date was present in person or represented by proxy at the Special Meeting and of the shares voted, approximately 99% voted in favor of adopting the merger proposal. A Form 8-K disclosing the full voting results will be filed with the Securities and Exchange Commission on July 16, 2019.
The closing of the merger will take place no later than two business days following when the last of the closing conditions of the merger have been satisfied or waived. At the close of the stock-for-stock transaction, Aratana stockholders will receive 0.1481 share of Elanco common stock and one contingent value right (CVR) for each share of Aratana common stock. The CVR of $0.25 per Aratana share will be paid in cash if capromorelin achieves certain sales levels on or before the end of 2021.
Date: July 22, 2019
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Source: PR Newswire
